Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma
- Authors
- Ahn, Hee Kyung; Kim, Seok Jin; Hwang, Deok Won; Ko, Young Hyeh; Tang, Tiffany; Lim, Soon Thye; Kim, Won Seog
- Issue Date
- Apr-2013
- Publisher
- SPRINGER
- Keywords
- Extranodal NK/Tcell lymphoma; Gemcitabine; Salvage
- Citation
- INVESTIGATIONAL NEW DRUGS, v.31, no.2, pp.469 - 472
- Journal Title
- INVESTIGATIONAL NEW DRUGS
- Volume
- 31
- Number
- 2
- Start Page
- 469
- End Page
- 472
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/14644
- DOI
- 10.1007/s10637-012-9889-4
- ISSN
- 0167-6997
- Abstract
- Extranodal natural killer/T-cell lymphoma (ENKL) has a dismal prognosis. Although L-asparaginase has shown promising efficacy as a frontline therapy, currently there are no treatment options after progression to an L-asparaginase-containing regimen. We report the results of gemcitabine-containing therapy in patients with relapsed or refractory ENKL. We retrospectively reviewed 20 patients with refractory or relapsed ENKL who received a gemcitabine-containing regimen between 2005 and 2011. The overall response rate was 40 % (8 of 20 patients) with a complete response (CR) rate of 20 % (n = 4) and a partial response (PR) rate of 20 % (n = 4). Four complete responders had a disease-free status for more than 7 months including two patients received autologous stem cell transplantation consolidation and L-aspraginase maintenance, respectively. The median progression-free survival of the 20 patients was 2.3 months; however, it was 7.3 months for eight responders (CR and PR). The median overall survival of the eight responders had not been reached at the time of analysis. Gemcitabine was effective in a subset of pretreated ENKL patients and can be considered as a salvage option.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/14644)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.